Health-related quality of life in recurrent platinum-sensitive ovarian cancer-results from the calypso trial

Annals of Oncology

Volumn 23, Issue 8, 2012, Pages 2020-2027

  Brundage, M ^a   Gropp, M ^b   Mefti, F ^c   Mann, K ^d   Lund, B ^e   Gebski, V ^f   Wolfram, G ^g   Reed, N ^h   Pignata, S ⁱ   Ferrero, A ^j   Brown, C ^f   Eisenhauer, E ^a   Pujade Lauraine, E ^k  

^a QUEEN S UNIVERSITY   (Canada)

^b Department of Medical Oncology   (Germany)

^c GINECO   (France)

^d National Health and Medical Research Council Clinical Trials Centre   (Australia)

^e AALBORG UNIVERSITY HOSPITAL   (Denmark)

^f UNIVERSITY OF SYDNEY   (Australia)

^g Arbeitsgemeinschaft Gynaekologische Onkologie Austria ^*  (Austria)

^h BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

ⁱ Multicenter Italian Trials in Ovarian Cancer   (Italy)

^j MAURIZIANO HOSPITAL   (Italy)

^k HÔTEL DIEU   (France)

more..

Author keywords

Carboplatin; Paclitaxel; Pegylated liposomal doxorubicin; Platinum sensitive; Quality of life; Recurrent ovarian cancer

Indexed keywords

CARBOPLATIN; DOXORUBICIN; PACLITAXEL;

ABDOMINAL PAIN; ADULT; ANOREXIA; ARTICLE; BODY IMAGE; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DYSPNEA; EORTC QOL QC30 QUESTIONNAIRE; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; OV28 OVARIAN CANCER MODULE; OVARY CANCER; PAIN; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; SEXUAL FUNCTION; SIDE EFFECT;

EID: 84864192169     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr583     Document Type: Article

References (15)

1. Covens A, Carey M, Bryson P et al. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer. Gynecol Oncol 2002; 85: 71-80.
2. Fung-Kee-Fung M, Oliver T, Elit L et al. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol 2007; 14: 195-208.
3. Pujade-Lauraine E, Wagner U, Avall-Lundqvist E et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 2010; 28: 3323-3329.
4. Pfisterer J, Plante M, Vergote I et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006; 24: 4699-4707.
5. Parmar MK, Ledermann JA, Colombo N et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003; 361: 2099-2106.
6. Gonzalez-Martin AJ, Calvo E, Bover I et al. Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol De Investigacion En Cancer De Ovario) study. Ann Oncol 2005; 16: 749-755.
7. Cantu MG, Buda A, Parma G et al. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol 2002; 20: 1232-1237.
8. Bolis G, Scarfone G, Giardina G et al. Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer. Gynecol Oncol 2001; 81: 3-9.
9. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-376.
10. Cull A, Howat S, Greimel E et al. EORTC Quality of Life Group [European Organization for Research and Treatment of Cancer]; Scottish Gynaecological Cancer Trials Group; Development of a European organization for research and treatment of cancer questionnaire module to assess the quality of life of ovarian cancer patients in clinical trials: a progress report. Eur J Cancer 2001; 37: 47-53.
11. Osoba D, Zee B, Pater J et al. Psychometric properties and responsiveness of the EORTC quality of life questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Qual Life Res 1994; 3: 353-364.
12. Osoba D, Bezjak A, Brundage M et al. Quality of Life Committee of the NCIC CTG analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of the National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer 2005; 41: 280-287.
13. Guyatt G, Schunemann H How can quality of life researchers make their work more useful to health workers and their patients? Qual Life Res 2007; 16: 1097-1105.
14. Sloan JA, Frost MH, Berzon R et al. Clinical Significance Consensus Meeting Group. The clinical significance of quality of life assessments in oncology: a summary for clinicians. Support Care Cancer 2006; 14: 988-998.
15. Greenhalgh J The applications of PROs in clinical practice: what are they, do they work, and why?. Qual Life Res 2009; 18: 115-123.